NM_000264.5:c.1418_1432delGCGTCCTGCTGGTTG
Variant summary
Our verdict is Uncertain significance. The variant received 5 ACMG points: 5P and 0B. PM4PP3PP5_Moderate
The NM_000264.5(PTCH1):c.1418_1432delGCGTCCTGCTGGTTG(p.Gly473_Val477del) variant causes a disruptive inframe deletion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. It is difficult to determine the true allele frequency of this variant because it is of type DEL_BIG, and the frequency of such variant types in population databases may be underestimated and unreliable. Variant has been reported in ClinVar as Likely pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. G473G) has been classified as Likely benign.
Frequency
Consequence
NM_000264.5 disruptive_inframe_deletion
Scores
Clinical Significance
Conservation
Publications
- basal cell nevus syndrome 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- holoprosencephaly 7Inheritance: AD Classification: DEFINITIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- holoprosencephalyInheritance: AD Classification: LIMITED Submitted by: Illumina
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 5 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PTCH1 | NM_000264.5 | c.1418_1432delGCGTCCTGCTGGTTG | p.Gly473_Val477del | disruptive_inframe_deletion | Exon 10 of 24 | ENST00000331920.11 | NP_000255.2 | |
| PTCH1 | NM_001083603.3 | c.1415_1429delGCGTCCTGCTGGTTG | p.Gly472_Val476del | disruptive_inframe_deletion | Exon 10 of 24 | ENST00000437951.6 | NP_001077072.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PTCH1 | ENST00000331920.11 | c.1418_1432delGCGTCCTGCTGGTTG | p.Gly473_Val477del | disruptive_inframe_deletion | Exon 10 of 24 | 5 | NM_000264.5 | ENSP00000332353.6 | ||
| PTCH1 | ENST00000437951.6 | c.1415_1429delGCGTCCTGCTGGTTG | p.Gly472_Val476del | disruptive_inframe_deletion | Exon 10 of 24 | 5 | NM_001083603.3 | ENSP00000389744.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Gorlin syndrome Pathogenic:1
This variant, c.1418_1432delGCGTCCTGCTGGTTG, results in the deletion of 5 amino acids of the PTCH1 protein (p.Gly473_Val477del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (ExAC no frequency). Family studies have indicated that this variant was not present in the parents of an individual affected with Gorlin syndrome, which suggests that it was de novo in that affected individual (Invitae). This in-frame deletion of 5 amino acids (Gly473-Val477) occurs within the third transmembrane domain (amino acids 473-498) of the PTCH1 protein (PMID: 16419085, 17021131, 8658145, 8981943). Experimental studies and prediction algorithms are not available for this variant, and the functional significance of the deleted amino acids is currently unknown. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at